BMO Capital Upgrades Fate Therapeutics to Outperform, Lowers Price Target to $47
BMO Capital analyst Etzer Darout upgrades Fate Therapeutics (NASDAQ:FATE) from Market Perform to Outperform and lowers the price target from $50 to $47.
Mizuho Maintains Buy on Public Service Enterprise, Lowers Price Target to $68
Mizuho analyst Paul Fremont maintains Public Service Enterprise (NYSE:PEG) with a Buy and lowers the price target from $73 to $68.
BMO Capital Downgrades Macrogenics to Market Perform, Lowers Price Target to $4
BMO Capital analyst Etzer Darout downgrades Macrogenics (NASDAQ:MGNX) from Outperform to Market Perform and lowers the price target from $31 to $4.
Janney Montgomery Scott Initiates Coverage On Gladstone Capital with Neutral Rating
Janney Montgomery Scott analyst John Rowan initiates coverage on Gladstone Capital (NASDAQ:GLAD) with a Neutral rating.
Goldman Sachs Initiates Coverage On Allscripts Healthcare with Neutral Rating, Announces Price Target of $21
Goldman Sachs analyst Cindy Motz initiates coverage on Allscripts Healthcare (NASDAQ:MDRX) with a Neutral rating and announces Price Target of $21.
Morgan Stanley Downgrades National Retail Props to Equal-Weight
Morgan Stanley analyst Ron Kamdem downgrades National Retail Props (NYSE:NNN) from Overweight to Equal-Weight.
Goldman Sachs Initiates Coverage On Willis Towers Watson with Neutral Rating, Announces Price Target of $227
Goldman Sachs analyst Robert Cox initiates coverage on Willis Towers Watson (NASDAQ:WTW) with a Neutral rating and announces Price Target of $227.
Morgan Stanley Downgrades Capital One Financial to Equal-Weight, Lowers Price Target to $126
Morgan Stanley analyst Betsy Graseck downgrades Capital One Financial (NYSE:COF) from Overweight to Equal-Weight and lowers the price target from $152 to $126.
Goldman Sachs Initiates Coverage On Arthur J. Gallagher with Buy Rating, Announces Price Target of $198
Goldman Sachs analyst Robert Cox initiates coverage on Arthur J. Gallagher (NYSE:AJG) with a Buy rating and announces Price Target of $198.
Stifel Upgrades Glaukos to Buy, Raises Price Target to $60
Stifel analyst Thomas Stephan upgrades Glaukos (NYSE:GKOS) from Hold to Buy and raises the price target from $40 to $60.